San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

The combination regimen of tucatinib, palbociclib, and letrozole in patients with hormone receptor–positive, HER2-positive breast cancer with brain metastases demonstrates an improved central nervous system progression-free survival in a small group of patients. Read More ›

Tucatinib-trastuzumab-capecitabine combination therapy has been shown to double the overall survival in patients with HER2-positive breast cancer with leptomeningeal metastases. Read More ›

Contemporaneous monitoring of HER2 status with circulating tumor cells may help to identify patients who may benefit from modifying the treatment approach with anti-HER2 therapy, through supplementation or switching to another therapy as necessary based on receptor switch. Read More ›

The potential role of the combination of pertuzumab, hormone therapy, plus an aromatase inhibitor as first-line treatment for HER2-positive metastatic or locally advanced breast cancer is further supported by the final analysis of the PERTAIN trial. Read More ›

Among patients with HER2-positive metastatic breast cancer, the healthcare resource utilization of brain metastases is significantly higher when compared with patients without brain metastases, underscoring the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease. Read More ›

Elderly patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, emphasizing the need for prospective studies to improve outcomes. Read More ›

This real-world study of community-based oncology clinics demonstrates that patients receive variable treatment patterns in later line settings, and there is no clear management strategy being utilized. With recently approved targeted therapies for HER2-positive metastatic breast cancer, improvements in patient outcomes are slowly being seen. Read More ›

A phase 2 trial of Enhertu (trastuzumab deruxtecan) in patients with HER2-positive metastatic breast cancer show high rates of positive results in patients who have been heavily pretreated. These results are preliminary and encouraging. Read More ›

Identified subpopulations of patients showed the largest absolute advances in 6-year invasive disease-free survival for pertuzumab compared with placebo. Read More ›

Breast cancer and its treatment impacts sexual health, which is an important topic for patients and clinicians to be able to address throughout the treatment process. Read More ›

Page 6 of 12

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications